FDA Orange Book · active-ingredient family
Tafenoquine succinate
Tafenoquine succinate is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:ARAKODA · NDA 210607
2
Brand (NDA)
0
Generics (ANDA)
4
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ARAKODARLD | 60 DEGREES PHARMS | NDA 210607 | — | Aug 08, 2018 | |
| KRINTAFELRLD | GLAXOSMITHKLINE | NDA 210795 | — | Jul 20, 2018 |
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10342791 | Dec 02, 2035 | in 9 yr 7 mo | U-2582 |
| 11744828 | Dec 02, 2035 | in 9 yr 7 mo | U-2582 |
| 10888558 | Dec 02, 2035 | in 9 yr 7 mo | U-2582 |
| 12616689 | Dec 02, 2035 | in 9 yr 7 mo | U-2582 |
Tafenoquine succinate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
